Role of the ubiquitin proteasome system in renal cell carcinoma

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) accounts for approximately 2.6% of all cancers in the United States. While early stage disease is curable by surgery, the median survival of metastatic disease is only 13 months. In the last decade, there has been considerable progress in understanding the genetics of RCC. The VHL tumor suppressor gene is inactivated in the majority of RCC cases. The VHL protein (pVHL) acts as an E3 ligase that targets HIF-1, the hypoxia inducible transcription factor, for degradation by the ubiquitin proteasome system (UPS). In RCC cases with mutant pVHL, HIF-1 is stabilized and aberrantly expressed in normoxia, leading to the activation of pro-survival genes such as vascular endothelial growth factor (VEGF). This review will focus on the defect in the UPS that underlies RCC and describe the development of novel therapies that target the UPS. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

Original languageEnglish (US)
Article numberS4
JournalBMC Biochemistry
Volume8
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 1 2007

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Renal Cell Carcinoma
Cells
Genes
Ubiquitin-Protein Ligases
Surgery
Vascular Endothelial Growth Factor A
Tumors
Proteins
Transcription Factors
Chemical activation
Protein Databases
Degradation
Defects
Tumor Suppressor Genes
Publications
History
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Role of the ubiquitin proteasome system in renal cell carcinoma. / Corn, Paul G.

In: BMC Biochemistry, Vol. 8, No. SUPPL. 1, S4, 01.12.2007.

Research output: Contribution to journalReview article

@article{300db3f8634b489abe0ee1798b11d606,
title = "Role of the ubiquitin proteasome system in renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) accounts for approximately 2.6{\%} of all cancers in the United States. While early stage disease is curable by surgery, the median survival of metastatic disease is only 13 months. In the last decade, there has been considerable progress in understanding the genetics of RCC. The VHL tumor suppressor gene is inactivated in the majority of RCC cases. The VHL protein (pVHL) acts as an E3 ligase that targets HIF-1, the hypoxia inducible transcription factor, for degradation by the ubiquitin proteasome system (UPS). In RCC cases with mutant pVHL, HIF-1 is stabilized and aberrantly expressed in normoxia, leading to the activation of pro-survival genes such as vascular endothelial growth factor (VEGF). This review will focus on the defect in the UPS that underlies RCC and describe the development of novel therapies that target the UPS. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).",
author = "Corn, {Paul G.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1186/1471-2091-8-S1-S4",
language = "English (US)",
volume = "8",
journal = "BMC Biochemistry",
issn = "1471-2091",
publisher = "BioMed Central",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Role of the ubiquitin proteasome system in renal cell carcinoma

AU - Corn, Paul G.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Renal cell carcinoma (RCC) accounts for approximately 2.6% of all cancers in the United States. While early stage disease is curable by surgery, the median survival of metastatic disease is only 13 months. In the last decade, there has been considerable progress in understanding the genetics of RCC. The VHL tumor suppressor gene is inactivated in the majority of RCC cases. The VHL protein (pVHL) acts as an E3 ligase that targets HIF-1, the hypoxia inducible transcription factor, for degradation by the ubiquitin proteasome system (UPS). In RCC cases with mutant pVHL, HIF-1 is stabilized and aberrantly expressed in normoxia, leading to the activation of pro-survival genes such as vascular endothelial growth factor (VEGF). This review will focus on the defect in the UPS that underlies RCC and describe the development of novel therapies that target the UPS. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

AB - Renal cell carcinoma (RCC) accounts for approximately 2.6% of all cancers in the United States. While early stage disease is curable by surgery, the median survival of metastatic disease is only 13 months. In the last decade, there has been considerable progress in understanding the genetics of RCC. The VHL tumor suppressor gene is inactivated in the majority of RCC cases. The VHL protein (pVHL) acts as an E3 ligase that targets HIF-1, the hypoxia inducible transcription factor, for degradation by the ubiquitin proteasome system (UPS). In RCC cases with mutant pVHL, HIF-1 is stabilized and aberrantly expressed in normoxia, leading to the activation of pro-survival genes such as vascular endothelial growth factor (VEGF). This review will focus on the defect in the UPS that underlies RCC and describe the development of novel therapies that target the UPS. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

UR - http://www.scopus.com/inward/record.url?scp=38449084670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449084670&partnerID=8YFLogxK

U2 - 10.1186/1471-2091-8-S1-S4

DO - 10.1186/1471-2091-8-S1-S4

M3 - Review article

C2 - 18047741

AN - SCOPUS:38449084670

VL - 8

JO - BMC Biochemistry

JF - BMC Biochemistry

SN - 1471-2091

IS - SUPPL. 1

M1 - S4

ER -